



ECIBC recommendation on 21 gene recurrence score testing for patients who have hormone receptor positive, HER-2 negative, lymph node negative or up to 3 lymph nodes positive invasive breast cancer to guide the use of chemotherapy (subgroup: lymph node negative)

Bibliography

Evidence of effects

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M et al. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer. *J Clin Oncol*. 2006 Aug 10;24(23):3726-34

Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. *Lancet Oncol*. 2010 Jan;11(1):55-65

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. *N Engl J Med*. 2018 Jul 12;379(2):111-121.

Values

Resources required

Vanderlaan BF, Broder MS, Chang EY, Oratz R, Bentley TG. Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer. *Am J Manag Care*. 2011;17(7):455-64.

Katz G, Romano O, Foa C, Vataire AL, Chantelard JV, Hervé R et al. Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France. *PLoS One*. 2015 Jun 18;10(6):e0128880.

Ward S, Scope A, Rafia R, Pandor A, Harnan S, Evans P et al. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis. *Health Technol Assess*. 2013 Oct;17(44):1-302.

Paulden M, Franek J, Pham B, Bedard PL, Trudeau M et al. Cost- effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer. *Value Health*. 2013 Jul-Aug;16(5):729-39.

Vataire AL, Laas E, Aballéa S, Gligorov J, Rouzier R, Chéreau E. [Cost- effectiveness of a chemotherapy predictive test] . *Bull Cancer*. 2012 Oct;99(10):907-14.

Jahn B, Rochau U, Kurzthaler C, Hubalek M, Miksad R, Sroczynski G et al. Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide



adjuvant chemotherapy in Austria. Springerplus. 2015;4:752. Published 2015 Dec 1. doi:10.1186/s40064-015-1440-6

Medical Advisory Secretariat. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence- based and economic analysis. Ont Health Technol Assess Ser. 2010;10(23):1-57.

Davidson JA, Cromwell I, Ellard SL, Lohrisch C, Gelmon KA, Shenkier T et al. A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score(R) assay in oestrogen receptor positive node negative breast cancer. Eur J Cancer. 2013 Jul;49(11):2469-75

Lyman GH, Cosler LE, Kuderer NM, Hornberger J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: An economic analysis based on prognostic and predictive validation studies. Cancer. 2007 Mar 15;109(6):1011-8.

Nerich V, Curtit E, Bazan F, Montcuquet P, Villanueva C, Chaigneau L et al. [Economic assessment of the routine use of Oncotype DX® assay for early breast cancer in Franche-Comte region]. Bull Cancer. 2014 Jul-Aug;101(7-8):681-9

Blohmer JU, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K et al. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early- stage breast cancer: a cost-effectiveness evaluation in the German setting. J Med Econ. 2013;16(1):30-40.

Cost effectiveness

Blok EJ, Bastiaannet E, van den Hout WB, Liefers GJ, Smit VTHBM, Kroep JR et al. Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe. Cancer Treat Rev. 2018 Jan;62:74-90

Wang SY, Dang W, Richman I, Mougalian SS, Evans SB, Gross CP. Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal. J Clin Oncol. 2018 Jun 1;36(16):1619-1627.

Equity

Acceptability

Feasibility
